Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bronchial Basal Cells for Chronic Respiratory Disease
NCT03153800Phase 1Unknown
- Sponsor
- Regend Therapeutics
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bronchial basal cells in chronic obstructive pulmonary disease (COPD), bronchiectasis and pulmonary fibrosis (PF), sponsored by Regend Therapeutics. Primary endpoints: Forced Expiratory Volume in One Second and Diffusion Capacity of Carbon Monoxide. Status: unknown.
02
Drugs
autologous bronchial basal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasispulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT03153800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153800.